Key Highlights
- Merck acquires Eyebiotech for up to $3 billion
- Eyebiotech’s Restoret™ to advance into pivotal trials in 2024
- Acquisition expands Merck’s ophthalmology pipeline
- Potential milestone payments up to $1.7 billion
Source: Business Wire
Notable Quotes
- “We continue to execute on our science-led business development strategy to expand and diversify our pipeline.” — Dr. Dean Y. Li, President, Merck Research Laboratories
- “The EyeBio team has successfully assembled a pipeline of novel candidates with the potential to provide new treatment options for patients with retinal disease.” — Dr. David R. Guyer, CEO and President at Eyebiotech
- “Less than three years ago, EyeBio was hatched to translate Dr. David Guyer’s idea for a potential new therapy for retinal diseases into a reality.” — Kate Bingham, Board Chair at EyeBio
SoHC's Take
This acquisition marks a significant step for Merck in broadening its reach within the ophthalmology sector. By integrating Eyebiotech’s innovative pipeline, particularly the promising Restoret™, Merck positions itself at the forefront of addressing retinal diseases like diabetic macular edema and neovascular age-related macular degeneration. This strategic move underscores Merck’s commitment to advancing its pipeline through targeted acquisitions, reinforcing its dedication to delivering cutting-edge treatments to patients worldwide.
